Skip to main content
PELL BMT logo

PELL BMT — Investor Relations & Filings

Ticker · 6949 ISIN · TW0006949001 TW Professional, scientific and technical activities
Open in API
Filings indexed 18 across all filing types
Latest filing 2026-05-20 Board/Management Inform…
Country TW Taiwan
Listing TW 6949

About PELL BMT

https://www.pellbmt.com

Pell Biologics & Medical Technology Co., Ltd. specializes in the research, development, and clinical application of advanced cell and gene therapies. The company’s core expertise lies in Chimeric Antigen Receptor T-cell (CAR-T) therapy, adoptive T-cell therapy, and stem cell-based regenerative medicine. Its primary R&D pipeline includes CD19 CAR-T treatments for B-cell lymphoma, alongside Cytokine-Induced Killer (CIK) and Dendritic Cell-Cytokine Induced Killer (DC-CIK) immunotherapies. In the field of regenerative medicine, the company develops adipose-derived stem cell (ADSC) applications for degenerative arthritis and tissue repair. Operating within GTP and GMP-compliant facilities, the company focuses on critical technologies for cell isolation, activation, and expansion to deliver personalized precision medicine and high-quality cellular products.

Recent filings

Filing Released Lang Actions
公告本公司研發主管異動案
Board/Management Information Classification · 95% confidence The document is a formal announcement from a listed company (ticker 6949) regarding the resignation of the old R&D head and appointment of a new interim R&D head. This is clearly a senior management change notice under Regulated Information (Taiwanese Exchange filing). It is not a full report but an announcement of a management change, matching the Board/Management Information category.
2026-05-20 Chinese
115年年報及股東會資料 — 2026_6949_20260618F13.pdf
AGM Information Classification · 90% confidence The document is the “議事手冊” (meeting handbook) for the company’s 115th Annual General Meeting, containing the AGM procedures, agenda items, and attachments including the prior year’s business report and audit committee report. It is clearly a set of materials prepared and distributed for the Annual General Meeting, rather than the standalone annual report itself or a simple announcement. Therefore, it should be classified as AGM Information.
2026-05-18 Chinese
115年年報及股東會資料 — 2026_6949_20260618F02.pdf
AGM Information Classification · 92% confidence The document is titled “115年股東常會 議事手冊” and contains the agenda, procedures, and attachments (business report, audit report, amendments to articles, governance rules, etc.) for the company’s Annual General Meeting. It is not the standalone annual report or financial statements but rather the meeting manual and materials distributed for the AGM itself. This matches the definition for AGM Information (AGM-R).
2026-05-18 Chinese
115年年報及股東會資料 — 2026_6949_20260618FE1.pdf
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a formal "Notice of Annual Shareholders’ Meeting" outlining the date, location and detailed agenda items for shareholder approval. It is not the meeting minutes, not the results, nor the financial statements themselves. Rather, it is part of the materials sent to shareholders to inform them of voting matters and solicit proxies for the upcoming meeting. Thus it falls under Proxy Solicitation & Information Statement (PSI).
2026-05-18 English
115年年報及股東會資料 — 2026_6949_20260618FE2.pdf
AGM Information Classification · 91% confidence The document is the full agenda and supporting materials for the 2026 Annual Shareholders’ Meeting, including meeting procedures, report items, ratification and discussion proposals, and annexes with business reports and financial statements—all typical materials distributed for an AGM. This matches the definition of AGM Information (AGM-R).
2026-05-18 English
115年年報及股東會資料 — 2026_6949_20260618F17.pdf
Major Shareholding Notification Classification · 85% confidence The document is a statutory disclosure of the top ten shareholders of 沛爾生技醫藥股份有限公司 as of April 20, 115 (ROC calendar), including their share counts, percentages and inter‐relationships (spouse, parent/subsidiary). This matches the definition of a Major Shareholding Notification (MRQ), which reports significant ownership levels. It is not announcing an AGM, financial results, or a change in capital structure, nor is it a report publication announcement. Therefore it should be classified as MRQ.
2026-05-18 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.